585 related articles for article (PubMed ID: 33977317)
1. Delayed follow-up of medical retina patients due to COVID-19: impact on disease activity and visual acuity.
Stone LG; Grinton ME; Talks JS
Graefes Arch Clin Exp Ophthalmol; 2021 Jul; 259(7):1773-1780. PubMed ID: 33977317
[TBL] [Abstract][Full Text] [Related]
2. Macula service evaluation and assessing priorities for anti-VEGF treatment in the light of COVID-19.
Stone LG; Devenport A; Stratton IM; Talks JS
Graefes Arch Clin Exp Ophthalmol; 2020 Dec; 258(12):2639-2645. PubMed ID: 32712708
[TBL] [Abstract][Full Text] [Related]
3. Changes in 12-month outcomes over time for age-related macular degeneration, diabetic macular oedema and retinal vein occlusion.
Bhandari S; Nguyen V; Hunt A; Gabrielle PH; Viola F; Mehta H; Manning L; Squirrell D; Arnold J; McAllister IL; Barthelmes D; Gillies M
Eye (Lond); 2023 Apr; 37(6):1145-1154. PubMed ID: 35508721
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Delay in Care among Patients Requiring Intravitreal Injections.
Song W; Singh RP; Rachitskaya AV
Ophthalmol Retina; 2021 Oct; 5(10):975-980. PubMed ID: 33395587
[TBL] [Abstract][Full Text] [Related]
5. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
Spooner K; Fraser-Bell S; Hong T; Chang A
Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
[TBL] [Abstract][Full Text] [Related]
6. Short term visual and structural outcomes of anti-vascular endothelial growth factor (anti-VEGF) treatment delay during the first COVID-19 wave: A pilot study.
Naravane AV; Mundae R; Zhou Y; Santilli C; van Kuijk FJGM; Nazari H; Yamanuha J; Emerson GG; Koozekanani DD; Montezuma SR
PLoS One; 2021; 16(2):e0247161. PubMed ID: 33596257
[TBL] [Abstract][Full Text] [Related]
7. Long-term Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: The LATAR Study: Report 1: Ten-Year, Real-World Outcomes.
Spooner K; Fraser-Bell S; Hong T; Phan L; Wong JG; Chang A
Ophthalmol Retina; 2021 Jun; 5(6):511-518. PubMed ID: 33007523
[TBL] [Abstract][Full Text] [Related]
8. Comparing vision and macular thickness in neovascular age-related macular degeneration, diabetic macular oedema and retinal vein occlusion patients treated with intravitreal antivascular endothelial growth factor injections in clinical practice.
Gurung RL; FitzGerald LM; McComish BJ; Hewitt AW; Verma N; Burdon KP
BMJ Open Ophthalmol; 2021; 6(1):e000749. PubMed ID: 34013049
[TBL] [Abstract][Full Text] [Related]
9. The effect of a brief, unplanned treatment delay on neovascular age-related macular degeneration patients: a retrospective cohort study.
Zehden JA; Ghosh A; Soundararajan S; Tsujimoto THM; Jiang H; Lin FC; Blahnik T; Fleischman D; Zhang AY
Sci Rep; 2023 Feb; 13(1):3156. PubMed ID: 36823223
[TBL] [Abstract][Full Text] [Related]
10. Machine Learning Can Predict Anti-VEGF Treatment Demand in a Treat-and-Extend Regimen for Patients with Neovascular AMD, DME, and RVO Associated Macular Edema.
Gallardo M; Munk MR; Kurmann T; De Zanet S; Mosinska A; Karagoz IK; Zinkernagel MS; Wolf S; Sznitman R
Ophthalmol Retina; 2021 Jul; 5(7):604-624. PubMed ID: 33971352
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal Ranibizumab for neovascular Age-related macular degeneration in clinical practice: five-year treatment outcomes.
Zhu M; Chew JK; Broadhead GK; Luo K; Joachim N; Hong T; Syed A; Chang AA
Graefes Arch Clin Exp Ophthalmol; 2015 Aug; 253(8):1217-25. PubMed ID: 25205618
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Eyes Lost to Follow-up with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Anti-Vascular Endothelial Growth Factor.
Soares RR; Mellen P; Garrigan H; Obeid A; Wibbelsman TD; Borkar D; Ho AC; Hsu J
Ophthalmol Retina; 2020 Feb; 4(2):134-140. PubMed ID: 31540854
[TBL] [Abstract][Full Text] [Related]
13. Long-term impact of delayed follow-up due to COVID-19 lockdown on patients with neovascular age-related macular degeneration.
Szegedi S; Ebner C; Miháltz K; Wachter T; Vécsei-Marlovits PV
BMC Ophthalmol; 2022 May; 22(1):228. PubMed ID: 35596203
[TBL] [Abstract][Full Text] [Related]
14. Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients: A Real-World Analysis of 49 485 Eyes.
Ciulla TA; Hussain RM; Pollack JS; Williams DF
Ophthalmol Retina; 2020 Jan; 4(1):19-30. PubMed ID: 31324588
[TBL] [Abstract][Full Text] [Related]
15. The impact of delayed anti-vascular endothelial growth factor treatment for retinal diseases during the COVID-19 lockdown.
Bulut MN; Sönmez HS; Gökçe G; Ağaçkesen A; Bulut K; Hacısalihoğlu A; Arsan A; Şimşek Ş
Photodiagnosis Photodyn Ther; 2021 Sep; 35():102449. PubMed ID: 34314862
[TBL] [Abstract][Full Text] [Related]
16. Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema.
Wong Y; Steel DHW; Habib MS; Stubbing-Moore A; Bajwa D; Avery PJ;
Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):733-742. PubMed ID: 27957600
[TBL] [Abstract][Full Text] [Related]
17. Outcome of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration in real-life setting.
Kataja M; Hujanen P; Huhtala H; Kaarniranta K; Tuulonen A; Uusitalo-Jarvinen H
Br J Ophthalmol; 2018 Jul; 102(7):959-965. PubMed ID: 29074495
[TBL] [Abstract][Full Text] [Related]
18. Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records.
Kiss S; Campbell J; Almony A; Shih V; Serbin M; LaPrise A; Wykoff CC
Ophthalmology; 2020 Sep; 127(9):1179-1188. PubMed ID: 32345477
[TBL] [Abstract][Full Text] [Related]
19. Outcomes in Retinal Vein Occlusions Presenting with Poor Visual Acuity Treated with Anti-Vascular Endothelial Growth Factor Therapy: Prognosis and Predictive Factors.
Light JG; Tian J; Wenick AS
Ophthalmol Retina; 2021 Sep; 5(9):888-900. PubMed ID: 33227561
[TBL] [Abstract][Full Text] [Related]
20. [Electrophysiological study of the visual pathway in anti-VEGF therapy of neovascular age-related macular degeneration combined with glaucoma].
Smirnova TV; Rud'ko AS; Andreeva IV; Karpilova MA
Vestn Oftalmol; 2019; 135(5):38-45. PubMed ID: 31714511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
